The DOI matches its Crossref record; 826 of the 826 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Open accessAbstract
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–800 of 826
Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder.
Marmar, C. R., Schoenfeld, F. B., Weiss, D. S., Metzler, T. J., Zatzick, D., Wu, R., Smiga, S., Tecott, L., & Neylan, T. C. (1996) · PubMed · Cited by 69
Refractory obsessive compulsive disorder and ECT.
Maletzky, B. M., McFarland, B., & Burt, A. (1994) · PubMed · Cited by 69
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
Mohr, N., Vythilingum, B., Emsley, R. A., & Stein, D. J. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200201000-00006 · Cited by 69
Cottraux, J. A., Note, I.-D., Cungi, C., Légeron, P., Heim, F., Chneiweiss, L., Bernard, G., & Bouvard, M. A. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.5.635 · Cited by 68
Taylor, F., & Cahill, L. F. (2002) · Journal of Traumatic Stress · doi:10.1023/a:1020145610914 · Cited by 68
Double-blind placebo-controlled pilot study of paroxetine for specific phobia
Benjamin, J., Ben-Zion, I. Z., Karbofsky, E., & Dannon, P. N. (2000) · Psychopharmacology · doi:10.1007/s002130000372 · Cited by 68
Failed Efficacy of Fluoxetine in the Treatment of Posttraumatic Stress Disorder
Martényi, F., Brown, E. B., & Caldwell, C. D. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31803308ce · Cited by 68
Rickels, K., DeMartinis, N. A., & Aufdembrinke, B. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00004 · Cited by 68
Salaberria, K., & Echeburua, E. (1998) · Behavior Modification · doi:10.1177/01454455980223003 · Cited by 68
Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
DeVeaugh-Geiss, J., Landau, P., & Katz, R. (1989) · PubMed · Cited by 68
Sepede, G., Berardis, D. D., Gambi, F., Campanella, D., Rovere, R. L., D'Amico, M., Cicconetti, A., Penna, L. L., Peca, S., Carano, A., et al. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000195108.01898.17 · Cited by 67
Clomipramine for panic disorder: I. the first 10 weeks of a long-term comparison with imipramine
Cassano, G., Petracca, A., Perugi, G., Nisita, C., Musetti, L., Mengali, F., & McNair, D. M. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90054-7 · Cited by 67
Selective Serotonin Reuptake Inhibitor Treatment for Generalized Anxiety Disorder
Ball, S. G., Kuhn, A., Wall, D., Shekhar, A., & Goddard, A. W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0113 · Cited by 66
Controlled-Release Paroxetine in the Treatment of Patients With Social Anxiety Disorder
Lepola, U. M., Bergtholdt, B., Lambert, J. S., Davy, K., & Ruggiero, L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0213 · Cited by 66
Seedat, S., & Stein, D. J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00005 · Cited by 65
Neuropsychiatric thalamocortical dysrhythmia: surgical implications
Jeanmonod, D., Schulman, J. J., Ramírez, R. R., Cancro, R., Lanz, M., Morel, A., Magnin, M., Siegemund, M., Kronberg, E., Ribary, U., et al. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(02)00116-x · Cited by 65
Perna, G., Bertani, A., Caldirola, D., Smeraldi, E., & Bellodi, L. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-14283 · Cited by 64 · cited 1×
“Some comparisons among the SSRIs did not reveal differences with regard to efficacy (Bandelow et al. 2004; Perna et al. 2001), while escitalopram showed evidence of superiority over citalopram on some outcome measures (Bandelow et al.”
ResultCognitive-behavioral therapy for panic disorder: current status.
Barlow, D. H. (1997) · PubMed · Cited by 64
Gepirone and Diazepam in Generalized Anxiety Disorder
Rickels, K., Schweizer, E. E., DeMartinis, N. A., Mandos, L. A., & Mercer, C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00006 · Cited by 64
Bonne, O. B., Shemer, Y., Gorali, Y., Katz, M., & Shalev, A. Y. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0309 · Cited by 64
A 2-year study of sertraline in the treatment of obsessive-compulsive disorder
Rasmussen, S. A., Hackett, E., DuBoff, E., Greist, J. H., Halaris, A. E., Koran, L. M., Liebowitz, M. R., Lydiard, R. B., McElroy, S. L., MENDELS, J., et al. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00003 · Cited by 63
Aliyev, N. A., & Aliyev, N. A. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.08.001 · Cited by 63
Remission Status After Long-Term Sertraline Treatment of Pediatric Obsessive-Compulsive Disorder
Wagner, K. D., Cook, E. H., Chung, H., & Messig, M. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322126340 · Cited by 63
Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study
Vaishnavi, S., Alamy, S., Zhang, W., Connor, K. M., & Davidson, J. R. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.027 · Cited by 63
Topiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder
Hollander, E., & Dell’Osso, B. M. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000199453.54799.cc · Cited by 63
Self-citationTopiramate in posttraumatic stress disorder: preliminary clinical observations.
Berlant, J. L. (2001) · PubMed · Cited by 63
Michelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
Charney, D. S., & Woods, S. W. (1989) · PubMed · Cited by 62
A placebo-controlled study of Kava kava in generalized anxiety disorder
Connor, K. M., & Davidson, J. R. T. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200207000-00005 · Cited by 62
Mörtberg, E., Karlsson, A., Fyring, C., & Sundin, Ö. (2005) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2005.07.005 · Cited by 61
Treatment of Posttraumatic Stress Disorder With Phenytoin: An Open-Label Pilot Study
Bremner, J. D., Mletzko, T., Welter, S., Siddiq, S., Reed, L., Williams, C., Heim, C. C., & Nemeroff, C. B. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1120 · Cited by 61
Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study
Amiaz, R., Fostick, L., Gershon, A. A., & Zohar, J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.006 · Cited by 61
Self-citationSCHWEIZER, E., RICKELS, K., De MARTINIS, N., CASE, G., & GARCÍA-ESPAÑA, F. (1998) · Psychological Medicine · doi:10.1017/s0033291798006540 · Cited by 60
Combining Pharmacotherapy with Cognitive‐Behavioral Interventions for Obsessive‐Compulsive Disorder
Cottraux, J., Bouvard, M. A., & Milliery, M. (2005) · Cognitive Behaviour Therapy · doi:10.1080/16506070510043750 · Cited by 60
Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder
McRae‐Clark, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., & Bayles-Dazet, W. (2004) · Depression and Anxiety · doi:10.1002/da.20008 · Cited by 60
An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder
Isolan, L., Pheula, G. F., Salum, G. A., Oswald, S. H., Rohde, L. A., & Manfro, G. G. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0007 · Cited by 60
UHLENHUTH, E. H., Balter, M. B., Ban, T. A., & Yang, K. C. C. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:3<107::aid-da2>3.0.co;2-t · Cited by 60
Determinants of Pharmacologic Treatment Failure in Panic Disorder
Cowley, D. S., Ha, E. H., & Roy‐Byrne, P. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1208 · Cited by 60
Emslie, G. J., & Judge, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10945.x · Cited by 60
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine
Mundo, E., Guglielmo, E., & Bellodi, L. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809000-00005 · Cited by 59
Davidson, J. R. T., Connor, K. M., Hertzberg, M. A., Weisler, R. H., Wilson, W. H., & Payne, V. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155817.21467.6c · Cited by 59
Lenox‐Smith, A., & Reynolds, A. (2003) · Europe PMC (PubMed Central) · Cited by 58
Potential effectiveness and safety of olanzapine in refractory panic disorder
Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005) · Depression and Anxiety · doi:10.1002/da.20050 · Cited by 58
Two-year follow-up of agoraphobics after exposure and imipramine
Cohen, S. D., Monteiro, W., & Marks, I. M. (1984) · The British Journal of Psychiatry · doi:10.1192/bjp.144.3.276 · Cited by 58
Symptom-specific effects of fluoxetine in post-traumatic stress disorder
Meltzer-Brody, S. E., Connor, K. M., Churchill, E., & Davidson, J. R. T. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015040-00006 · Cited by 58
The galway study of panic disorder I:
Fahy, T. J., O'Rourke, D., Brophy, J., Schazmann, W., & Sciascia, S. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90094-m · Cited by 58
Lorazepam Vs. Alprazolam in the Treatment of Panic Disorder
Schweizer, E. E., Pohl, R. B., Balon, R., Fox, I., Rickels, K., & Yeragani, V. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014489 · Cited by 58
Dell’Osso, B. M., Mundo, E., Marazziti, D., & Altamura, A. C. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107079865 · Cited by 58
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Self-citationBlier, P., & Bergeron, R. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00005 · Cited by 57
Cognitive Therapy for Panic Disorder
(2013) · PsycEXTRA Dataset · doi:10.1037/e505072006-001 · Cited by 57
Marazziti, D., Pfanner, C., Dell’osso, B., Ciapparelli, A., Presta, S., Corretti, G., Di Nasso, E., Mungai, F., & Dell’osso, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053299 · Cited by 56
Clonazepam in the Treatment of Panic Disorder
Beauclair, L., FONTAINE, R., Annable, L., Holobow, N. E., & Chouinard, G. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00005 · Cited by 56
Moclobemide and fluoxetine for panic disorder
Tiller, J. W. G., Bouwer, C., Behnke, K., & For the International Panic Disorder Study Group (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014164 · Cited by 56
Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder
Escalona, R., Cañive, J. M., Calais, L. A., & Davidson, J. R. T. (2002) · Depression and Anxiety · doi:10.1002/da.1082 · Cited by 56
Response of panic disorder to fixed doses of alprazolam or imipramine
UHLENHUTH, E. H., Matuzas, W., Glass, R. M., & Easton, C. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90009-8 · Cited by 56
Inositol in the Treatment of Trichotillomania and Compulsive Skin Picking
Seedat, S., Stein, D. J., & Harvey, B. H. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0112f · Cited by 56
Asakura, S., Tajima, O., & Koyama, T. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006602 · Cited by 56
Fluvoxamine in Civilians With Posttraumatic Stress Disorder
Davidson, J. R. T., Weisler, R. H., Malik, M. L., & Tupler, L. A. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199802000-00020 · Cited by 56
WCA Recommendations for the Long-Term Treatment of Panic Disorder
Pollack, M. H., Allgulander, C., Bandelow, B., Cassano, G. B., Greist, J. H., Hollander, E., Nutt, D., Okasha, A., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s109285290000691x · Cited by 55
Self-citationTaylor, C. B., HAYWARD, C., King, R., Ehlers, A., Margraf, J., Maddock, R. J., Clark, D. B., Roth, W. T., & Agras, W. S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199004000-00006 · Cited by 55
Psychosocial adaptation in adolescents and young adults with Marfan syndrome: an exploratory study.
Tongerloo, A. V., & Paepe, A. D. (1998) · Journal of Medical Genetics · doi:10.1136/jmg.35.5.405 · Cited by 55
Clonazepam in the treatment of social phobia: a pilot study.
Munjack, D. J., Baltazar, P. L., Bohn, P., CABE, D. D., & Appleton, A. A. (1990) · PubMed · Cited by 54
James, I. M., Burgoyne, W., & Savage, I. (1983) · Journal of the Royal Society of Medicine · doi:10.1177/014107688307600308 · Cited by 54
Bandelow, B., Behnke, K., Lenoir, S., Hendriks, G., Alkın, T., Goebel, C., & Clary, C. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0317 · Cited by 54
Self-citationThe Use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial1
Bandelow, B., Broocks, A., Pekrun, G., George, A., Meyer, T., Pralle, L., Bartmann, U., Hillmer-Vogel, U., & Rüther, E. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-12982 · Cited by 53
Self-citationKalin, N. H., Davidson, R. J., Irwin, W., Warner, G., Orendi, J. L., Sutton, S. K., Mock, B. J., Sorenson, J. A., Lowe, M. J., & Turski, P. A. (1997) · PubMed · Cited by 53
Levetiracetam for Treatment-Refractory Posttraumatic Stress Disorder
Kinrys, G., Wygant, L. E., Pardo, T. B., & Melo, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0206 · Cited by 53
Storch, E. A., Lehmkuhl, H. D., Geffken, G. R., Touchton, A., & Murphy, T. K. (2007) · Depression and Anxiety · doi:10.1002/da.20303 · Cited by 53
Venlafaxine in Obsessive-compulsive Disorder
Yaryura-Tobias, J. A. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830070103016 · Cited by 53
WCA Recommendations for the Long-Term Treatment of Social Phobia
Ameringen, M. V., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., et al. (2003) · CNS Spectrums · doi:10.1017/s1092852900006933 · Cited by 53
Self-citationPsychological Strategies for Discontinuing Benzodiazepine Treatment
Spiegel, D. A. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00004 · Cited by 53
Milanfranchi, A., Ravagli, S., Lensi, P., Marazziti, D., & Cassano, G. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00002 · Cited by 52
Strand, M., Hetta, J. E., Rosen, A., Sörensen, S., Malmström, R. E., Fabian, C. J., Marits, K., Vetterskog, K., Liljestrand, Ä., & Hegen, C. (1990) · PubMed · Cited by 52
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52 · cited 1×
“While no universally accepted criteria exist, a commonly used threshold for response is a 50% improvement in the total score of a commonly used rating scale (e.g., the HAMA), however, this definition is somehow arbitrary and not fully supported by clinical data (Bandelow 2006; Bandelow et al. 2006).”
Self-citationStein, M. B., Norton, G. R., Walker, J. R., Chartier, M., & Graham, R. M. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00154-2 · Cited by 51
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder
Mbaya, P., Alam, F. D., Ashim, S., & BENNETT, D. H. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.834 · Cited by 51
Ferguson, J. M., Khan, A., Mangano, R. M., Entsuah, R., & Tzanis, E. L. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0108 · Cited by 50
Mundo, E., Maina, G., & Uslenghi, C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015020-00002 · Cited by 50
Open-Label Trial of Escitalopram in the Treatment of Posttraumatic Stress Disorder
Robert, S., Hamner, M. B., Ulmer, H. G., Lorberbaum, J. P., & Durkalsk, V. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1005 · Cited by 50
Bertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., & Bellodi, L. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832593 · Cited by 49
Pharmacotherapy for obsessive-compulsive disorder.
Greist, J. H., & Jefferson, J. W. (1998) · PubMed · Cited by 49
Mindus, P., Edman, G., & Andréewitch, S. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb05383.x · Cited by 49
Tiagabine Improves Panic and Agoraphobia in Panic Disorder Patients
Zwanzger, P., Baghai, T. C., Schüle, C., Minov, C., Padberg, F., Möller, H., & Rupprecht, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0813d · Cited by 49
Self-citationStein, D. J., Westenberg, H. G. M., Yang, H., Li, D., & Barbato, L. M. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570300364x · Cited by 49
Hembree, E. A., Riggs, D. S., Kozak, M. J., Franklin, M. E., & Foa, E. B. (2003) · CNS Spectrums · doi:10.1017/s1092852900018629 · Cited by 49
Psychotropic medications in pregnant women: treatment dilemmas
Mitchell, P. B., & Austin, M. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb126837.x · Cited by 49
A Fixed-Dose Study of Alprazolam 2 mg, Alprazolam 6 mg, and Placebo in Panic Disorder
Lydiard, R. B., Lesser, I. M., BALLENGER, J. C., Rubín, R. T., LARAIA, M., & DuPont, R. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199204000-00004 · Cited by 48
Hackett, D., Haudiquet, V., & Salinas, E. O. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00046-4 · Cited by 48
A Controlled Study of Alprazolam and Propranolol in
Ravaris, C. L., Friedman, M. J., Hauri, P., & McHugo, G. J. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199112000-00003 · Cited by 48
Excretion of Psychotropic Drugs into Breast Milk
Spigset, O., & Hägg, S. (1998) · CNS Drugs · doi:10.2165/00023210-199809020-00004 · Cited by 48
A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder.
Rizley, R. C., Rj, K., McNair, D. M., & Frankenthaler, L. M. (1986) · PubMed · Cited by 48
Andrews, G., Corry, J., Browne, M. A. O., & Shepherd, L. (2003) · Australian & New Zealand Journal of Psychiatry · Cited by 48
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A. A., & KAPRINIS, G. S. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00003 · Cited by 47
Quetiapine Augmentation in Obsessive-Compulsive Disorder Resistant to Serotonin Reuptake Inhibitors
Bogan, A. M., Koran, L. M., Chuong, H. W., Vapnik, T., & Bystritsky, A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0110 · Cited by 47
Önder, E., Tural, Ü., & Aker, T. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.03.007 · Cited by 47
Pilot Trial of Memantine in the Treatment of Posttraumatic Stress Disorder
Battista, M. A., Hierholzer, R. W., Khouzam, H. R., Barlow, A. S., & O’Toole, S. K. (2007) · Psychiatry · doi:10.1521/psyc.2007.70.2.167 · Cited by 47
WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder
Stein, D. J., Bandelow, B., Hollander, E., Nutt, D., Okasha, A., Pollack, M. H., Swinson, R. P., & Zohar, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900006921 · Cited by 47
Self-citationPollack, M. H., Tiller, J., Xie, F., & Trivedi, M. H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b45f · Cited by 47
Committee Opinion No. 354: Treatment With Selective Serotonin Reuptake Inhibitors During Pregnancy
(2006) · Obstetrics and Gynecology · doi:10.1097/00006250-200612000-00058 · Cited by 47
Kava in generalized anxiety disorder: three placebo-controlled trials
Connor, K. M., Payne, V., & Davidson, J. R. T. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00001 · Cited by 46
Allgulander, C., Nutt, D., Detke, M. J., Erickson, J., Spann, M., Walker, D. J., Ball, S. G., & Russell, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091588 · Cited by 46
Jenike, M. A., & Baer, L. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.10.1393 · Cited by 46
Behavioral effects of naloxone infusion in obsessive-compulsive disorder
Keuler, D. J., Altemus, M. M., Michelson, D., Greenberg, B. D., & Murphy, D. L. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00632-x · Cited by 45
Successful treatment of obsessive-compulsive disorder with ECT
Mellman, L. A., & Gorman, J. M. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.4.596 · Cited by 44
The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder
Krüger, M. B., & Dahl, A. A. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014163 · Cited by 44
Gladsjo, J. A., Rapaport, M. H., McKinney, R., Auerbach, M., Hahn, T., Rabin, A., Oliver, T., Hazen, A. L., & Judd, L. L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00003 · Cited by 44
Sharp, D. M., Power, K., Simpson, R., Swanson, V., & Anstee, J. A. (1997) · Europe PMC (PubMed Central) · Cited by 43
Clinical Experience with Mirtazapine in the Treatment of Panic Disorder
Carpenter, L. L., Leon, Z., Yasmin, S., & Price, L. H. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022394415585 · Cited by 43
Tiagabine for social anxiety disorder
Dunlop, B. W., Papp, L. A., Garlow, S. J., Weiss, P., Knight, B. T., & Ninan, P. T. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.846 · Cited by 43
Open trial of citalopram in adults with post-traumatic stress disorder
Seedat, S., Stein, D. J., & Emsley, R. A. (2000) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145700001899 · Cited by 43
An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis, N. A., Schweizer, E. E., & Rickels, K. (1996) · PubMed · Cited by 42
Maintenance drug therapy of panic disorder
Curtis, G. C., Massana, J., Udina, C., Ayuso, J. L., Cassano, G. B., & Perugi, G. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90023-u · Cited by 42
Toward an integrative understanding of social phobia.
Li, D., Chokka, P. R., & Tibbo, P. G. (2001) · PubMed · Cited by 42
Long-term pharmacological treatment of generalized anxiety disorder
Mahé, V., & Balogh, A. T. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015020-00006 · Cited by 41
Sertraline Versus Imipramine Treatment of Comorbid Panic Disorder and Major Depressive Disorder
Lepola, U. M., Arató, M., Zhu, Y., & Austin, C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0606 · Cited by 41
Exposure-based integrated vs. pure psychodynamic treatment of agoraphobic inpatients.
Hoffart, A., & Matinsen, E. W. (1990) · Psychotherapy · doi:10.1037/0033-3204.27.2.210 · Cited by 40
Kaminer, D., & Stein, D. J. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029902 · Cited by 40
Fontaine, R., Annable, L., Chouinard, G., & OGILVIE, R. I. (1983) · PubMed · Cited by 40
Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia
DeVane, C. L., Ware, M. R., Emmanuel, N. P., Brawman‐Mintzer, O., Morton, W. A., Villarreal, G., & Lydiard, R. B. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00004 · Cited by 40
Nicotine treatment of obsessive–compulsive disorder
Lundberg, S., Carlsson, A., Norfeldt, P., & Carlsson, M. L. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.014 · Cited by 40
Murphy, M. T., Michelson, L. K., Marchione, K., Marchione, N., & Testa, S. (1998) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(98)00003-6 · Cited by 39 · cited 1×
“Superiority to a pill placebo or a psychological placebo was demonstrated in some studies (Barlow et al. 2000; Beck et al. 1992; Carlbring et al. 2006; Klosko et al. 1990; Marks et al. 1983, 1993; Mavissakalian and Michelson 1983; Murphy et al. 1998), while others found no difference to the control condition (Bakker e…”
BackgroundSodium valproate and clonazepam for treatment-resistant panic disorder.
Ontiveros, A., & Fontaine, R. (1992) · PubMed · Cited by 39
Death by tricyclic: the real antidepressant scandal?
Nutt, D. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051987 · Cited by 39
Nair, N. P. V., Bakish, D., Saxena, B., Amin, M., Schwartz, G. J., & West, T. E. G. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:4<192::aid-anxi6>3.0.co;2-q · Cited by 39
Bakish, D., Cl, H., Filteau, M., Charbonneau, Y., Fraser, G. L., West, D., Thibaudeau, C. A., & Raine, D. (1996) · PubMed · Cited by 39
Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
Önder, E., Tural, Ü., & Gökbakan, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0798-z · Cited by 38
Frameless stereotactic subcaudate tractotomy for intractable obsessive–compulsive disorder
Woerdeman, P. A., Willems, P. W. A., Noordmans, H. J., van der Sprenkel, J. W. B., & van Rijen, P. C. (2006) · Acta Neurochirurgica · doi:10.1007/s00701-006-0769-6 · Cited by 38
Lydiard, R. B., Ballenger, J. C., & Rickels, A. K. (1997) · The Journal of Clinical Psychiatry · Cited by 38
Meibach, R. C., Dunner, D., Wilson, L. G., Ishiki, D., & Dager, S. R. (1987) · PubMed · Cited by 38
Escitalopram in specific phobia: results of a placebo-controlled pilot trial
Alamy, S., Zhang, W., Varia, I. M., Davidson, J. R. T., & Connor, K. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107080796 · Cited by 37
Ansseau, M., Olié, J., von Frenckell, R., Jourdain, G., Stehlé, B., & Guillet, P. (1991) · Psychopharmacology · doi:10.1007/bf02245646 · Cited by 37
Hamner, M. B., & Frueh, B. C. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809000-00008 · Cited by 36
The Benefit of an Insight-Oriented and Experiential Approach on Panic and Agoraphobia Symptoms
Teusch, L., Böhme, H., & Gastpar, M. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000289151 · Cited by 36
Kamijima, K., Murasaki, M., Asai, M., Higuchi, T., Nakajima, T., Taga, C., & Matsunaga, H. (2004) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01278.x · Cited by 35
Nadiga, D. N., Hensley, P. L., & UHLENHUTH, E. H. (2003) · Depression and Anxiety · doi:10.1002/da.10084 · Cited by 35
Beck, A. T., Steer, R. A., & Sanderson, W. C. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.10.1412-a · Cited by 35
Bupropion Sustained Release for Panic Disorder
Simon, N. M., Emmanuel, N. P., Emmanuel, N., Worthington, J. J., Ballenger, J. F., Korbly, N. B., Worthington, J. J., Pollack, M. H., Kinrys, G., Farach, F. J., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4163 · Cited by 34
Boyer, W. F., & Feighner, J. P. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00006 · Cited by 34
Spivak, B., Strous, R. D., Shaked, G., Shabash, E., Kotler, M., & Weizman, A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203195.65710.f0 · Cited by 34
Are SSRIs safe for pregnant and breastfeeding women?
Misri, S. K., Burgmann, A., & Kostaras, D. (2000) · PubMed · Cited by 34
Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study
Seedat, S., van Oudtshoorn, E. V. R., Muller, J. E., Mohr, N., & Stein, D. J. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200309000-00004 · Cited by 33
Mukaddes, N. M., Abalı, O., & Kaynak, N. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01139.x · Cited by 33
Citalopram in refractory obsessive-compulsive disorder: an open study
Marazziti, D., Dell’Osso, L., Gemignani, A., Ciapparelli, A., Presta, S., Nasso, E. D., Pfanner, C., & Cassano, G. B. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200107000-00005 · Cited by 33
Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder.
Worthington, J. J., Pollack, M. H., Otto, M. W., McLean, R. Y. S., Moroz, G., & Rosenbaum, J. F. (1998) · PubMed · Cited by 33
Control groups in pharmacotherapy and psychotherapy evaluations.
Klein, D. F. (1997) · Prevention & Treatment · doi:10.1037/1522-3736.1.1.11a · Cited by 33
Yoshimura, R., Kaneko, S., Shinkai, K., & Nakamura, J. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01519.x · Cited by 32
ADVANCES IN THE NEUROBIOLOGY OF OBSESSIVE-COMPULSIVE DISORDER
Stein, D. J. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70180-5 · Cited by 32
Zolpidem for Insomnia Related to PTSD
Dieperink, M. E., & Drogemuller, L. (1999) · Psychiatric Services · doi:10.1176/ps.50.3.421 · Cited by 32
Lydiard, R. B., Jc, B., & Rickels, K. (1997) · PubMed · Cited by 32
Benzodiazepines in the Treatment of Anxiety
Rickels, K. (1982) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1982.36.3.358 · Cited by 32
Bromazepam and Diazepam in Generalized Anxiety
FONTAINE, R., Annable, L., Chouinard, G., & OGILVIE, R. I. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198304000-00005 · Cited by 32
Stein, D. J., Berk, M., Els, C., Emsley, R. A., Gittelson, L., Wilson, D., Oakes, R., & Hunter, B. (1999) · PubMed · Cited by 31
Buspirone in the Treatment of Panic Disorder: A Controlled Pilot Comparison with Clorazepate
Schweizer, E. E., & Rickels, K. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808000-00033 · Cited by 31
The efficacy of milnacipran in panic disorder: an open trial
Blaya, C., Seganfredo, A. C. G., Dornelles, M., Torres, M., Paludo, A. P., Heldt, E., & Manfro, G. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32802c7bf5 · Cited by 31
Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo
Bandelow, B., Stein, D. J., Dolberg, O. T., Andersen, H., & Baldwin, D. S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-984398 · Cited by 31
Self-citationThe Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Lactation: Current Knowledge
Misri, S. K., Kostaras, D., & Kostaras, X. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500309 · Cited by 31
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy.
Hoffart, A., Due-Madsen, J., Lande, B., Gude, T., Bille, H., & Torgersen, S. O. (1993) · PubMed · Cited by 29
Interactive Model of Therapeutic Response in Panic Disorder: Moclobemide, a Case in Point
UHLENHUTH, E. H., Warner, T. D., & Matuzas, W. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00008 · Cited by 29
Alprazolam and Diazepam in the Treatment of Generalized Anxiety
Elie, R., & Lamontagne, Y. (1984) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198406000-00002 · Cited by 29
Smith, D. E., & Landry, M. J. (1990) · Journal of Psychiatric Research · doi:10.1016/0022-3956(90)90046-s · Cited by 29
What can be learnt from the natural history of anxiety disorders?
Rubio, G., & López-Ibor, J. J. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.09.007 · Cited by 29
Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia
Mavissakalian, M., & Perel, J. M. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1053 · Cited by 29
Tiffon, L., Coplan, J. D., Papp, L. A., & Gorman, J. M. (1994) · PubMed · Cited by 28
A Clinical Trial of Buspirone and Diazepam in the Treatment of Generalized Anxiety Disorder *
Ross, C. A., & Matas, M. (1987) · The Canadian Journal of Psychiatry · doi:10.1177/070674378703200505 · Cited by 28
Nutt, D., Allgulander, C., Lecrubier, Y., Peters, T., & Wïttchen, H. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091068 · Cited by 28
Successful augmentation with aripiprazole in clomipramine-refractory obsessive–compulsive disorder
da Rocha, F. F., & Corrêa, H. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.008 · Cited by 28
Anxiolytic Effects of Vigabatrin in Panic Disorder
Zwanzger, P., Baghai, T. C., Boerner, R. J., Möller, H., & Rupprecht, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00017 · Cited by 28
Self-citationMaintenance ECT for refractory obsessive-compulsive disorder
Husain, M. M., Lewis, S. F., & Thornton, W. L. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1899c · Cited by 28
Sandmann, J., Lörch, B., Bandelow, B., Härtter, S., Winter, P., Hiemke, C., & Benkert, O. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979311 · Cited by 27
Self-citationOndansetron in the treatment of panic disorder
Schneier, F. R., Garfinkel, R. S., Kennedy, B., Campeas, R. B., Fallon, B., Marshall, R. D., O'Donnell, L., Hogan, T., & Liebowitz, M. R. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:4<199::aid-anxi7>3.0.co;2-j · Cited by 27
Usefulness of Olanzapine in Refractory Panic Attacks
Khaldi, S., Kornreich, C., Dan, B., & Pelc, I. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00015 · Cited by 26
Sharp, S., & Hellings, J. A. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626050-00002 · Cited by 26
Controlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder
Woods, S. W., Nagy, L. M., Koleszar, A. S., Krystal, J. H., Heninger, G. R., & Charney, D. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199202000-00006 · Cited by 26
Double‐blind pilot trial of desipramine versus fluoxetine in panic patients
Bystritsky, A., Rosen, R. M., Murphy, K. J., Bohn, P. W., Keys, S. A., & Vapnik, T. (1994) · Anxiety · doi:10.1002/anxi.3070010608 · Cited by 25
Rickels, K., Mathew, S. J., Banov, M. D., Zimbroff, D. L., Oshana, S. C., Parsons, E. C., Donahue, S., Kauffman, M. G., Iyer, G. R., & Reinhard, J. F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774de · Cited by 25
Etxebeste, M. A., ARAGÝS, E., Malo, P., & PACHECO, L. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.659-a · Cited by 25
Electroconvulsive Therapy in Obsessive-Compulsive Disorder.
Khanna, S., Gangadhar, B. N., Sinha, V., Rajendra, P. N., & Sm, C. (1988) · PubMed · Cited by 25
Efficacy of Open-Label Nefazodone Treatment in Patients With Panic Disorder
Papp, L. A., Coplan, J. D., Martinez, J. M., de Jesus, M., & Gorman, J. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200010000-00009 · Cited by 24
Agid, O., & Lerer, B. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0112d · Cited by 24
Gabapentin and Posttraumatic Stress Disorder
Malek-Ahmadi, P. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c082 · Cited by 24
Cournoyer, J. (1986) · The Canadian Journal of Psychiatry · doi:10.1177/070674378603100410 · Cited by 23
A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan
Kamijima, K., Kuboki, T., Kumano, H., Burt, T., Cohen, G., Arano, I., & Hamasaki, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000171518.25963.63 · Cited by 23
Resistant social anxiety disorder response to Escitalopram.
Pallanti, S., & Quercioli, L. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-35 · Cited by 23
BELLAMY, W. A. (1947) · BMJ · doi:10.1136/bmj.1.4496.313-d · Cited by 22
Kawahara, T., Ueda, Y., & Mitsuyama, Y. (2000) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2000.00760.x · Cited by 22
The Use of Selective Serotonin Reuptake Inhibitors in Children and Adolescents with Major Depression
Scahill, L. D., Hamrin, V., & Pachler, M. C. (2005) · Journal of Child and Adolescent Psychiatric Nursing · doi:10.1111/j.1744-6171.2005.00015.x · Cited by 22
Marfan's Syndrome and Schizophrenia: A Case Report
Romano, J., & Linares, R. L. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800140102017 · Cited by 21
Neuropsychological Outcome from Psychosurgery for Obsessive-Compulsive Disorder
Cumming, S., Hay, P., Lee, T., & Sachdev, P. S. (1995) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048679509075924 · Cited by 21
Simpson, K. L., & Noble, S. (2000) · CNS Drugs · doi:10.2165/00023210-200014040-00005 · Cited by 21
Cognitive-behavior Therapy for Generalized Anxiety Disorder
Harvey, A. G., & Rapee, R. M. (1995) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30027-3 · Cited by 20
Alpert, M., Sabeti, M., Kushner, M. G., Beitman, B. D., Russell, J. L., Thiele, J. R., & Mukerji, V. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90909-i · Cited by 20
Treatment of Panic Disorder: Focus on Paroxetine
Pollack, M. H., Doyle, M. A. A. C., & ba, B. (2015) · Psychopharmacology Bulletin · doi:10.64719/pb.7060 · Cited by 19
Mercuro, G., Ruscazio, M., Zoncu, S., Montisci, R., Cherchi, A., Carpiniello, B., & Rudas, N. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200311 · Cited by 19
What treatments do patients with panic disorder and agoraphobia get?
Bandelow, B., Sievert, K., Röthemeyer, M., Hajak, G., & Rüther, E. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02193090 · Cited by 19
Self-citationAripiprazole Augmentation of Clomipramine-Refractory Obsessive-Compulsive Disorder
Friedman, S., Abdallah, T. A., Oumaya, M., Rouillon, F., & Guelfi, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624d · Cited by 19
A review of the safety of selective serotonin reuptake inhibitors during pregnancy
GOLDSTEIN, D. J., & Sundell, K. L. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199907)14:5<319::aid-hup99>3.0.co;2-d · Cited by 19
Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
Zitterl, W., Meszaros, K., Hornik, K., Twaroch, T., Dossenbach, M. R. K., Zitterl‐Eglseer, K., & Zapotoczky, H. G. (1999) · PubMed · Cited by 17
Sertraline and exposure therapy in social phobia
Bandelow, B. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.3.271 · Cited by 16
Self-citationBradwejn, J. (1993) · PubMed · Cited by 16
Research works printed but not linked: 116
- Altshuler LL, 2001, Postgrad Med, 1
- Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
- Bakish D, 1996, Psychopharmacol Bull, 32, 135
- Ballenger JC, 2001, J Clin Psychiatry, 62, 53
- Bandelow B, 2004, Br J Psychiatry, 184, 271, 10.1192/bjp.184.3.271 · DOI
- Bandelow B, 2002, Eur Neuropsychopharmacol, 12, S364, 10.1016/S0924-977X(02)80585-5 · doi:10.1016/s0924-977x(02)80585-5
- Bradwejn J, 1993, Can J Psychiatry, 38, S109
- Braun P, 1990, J Clin Psychiatry, 51, 236
- Bystritsky A, 2008, Psychopharmacol Bull, 41, 46
- 10.3109/10401239909147053 · doi:10.3109/10401239909147053
- Chao IL, 2004, Pharmacopsychiatry, 37, 239, 10.1055/s-2004-832600 · DOI
- Charney DS, 1989, J Clin Psychiatry, 50, 418
- Charney DS, 1986, J Clin Psychiatry, 47, 580
- Chouinard G, 1990, Psychopharmacol Bull, 26, 279
- 10.3109/10401230490281609 · doi:10.3109/10401230490281609
- Davis LL, 2008, Psychopharmacol Bull, 41, 8
- DeVeaugh-Geiss J, 1989, Psychopharmacol Bull, 25, 36
- Dieleman GC, 2008, Tijdschr Psychiatr, 50, 43
- Dunner DL, 1986, J Clin Psychiatry, 47, 458
- Eriksson T, 2007, Int Clin Psychopharmacol, 22, 57
- Feighner JP, 1987, J Clin Psychiatry (Suppl), 48, 3
- Feighner JP, 1982, J Clin Psychiatry, 43, 103
- Feltner DE, 2003, J Clin Psychopharmacol, 23, 240
- Ferreri M, 1994, Encéphale, 20, 785
- 10.1037/0022-006X.65.6.1026 · doi:10.1037/0022-006x.65.6.1026
- Fesler FA, 1991, J Clin Psychiatry, 52, 361
- Foa EB, 2000, J Clin Psychiatry, 61, 43
- Frommberger U, 2004, Fortschr Neurol Psychiatr, 72, 411, 10.1055/s-2004-818455 · doi:10.1055/s-2004-818455
- Gelpin E, 1996, J Clin Psychiatry, 57, 390
- Gruber RP, 1971, Dis Nerv Syst, 32, 180
- Hamner MB, 2001, Ann Clin Psychiatry, 13, 141, 10.3109/10401230109148960 · DOI
- 10.3109/10401230009147096 · DOI · Paper page
- Hoehn-Saric R, 1988, J Clin Psychiatry, 49, 293
- Hoffart A, 1993, J Clin Psychiatry, 54, 481
- 10.1037/0022-006X.72.3.393 · DOI
- Hofmann SG, 2008, J Clin Psychiatry, e1
- Husain MM, 1993, Am J Psychiatry, 150, 1899
- Jenike MA, 1991, J Clin Psychiatry, 52, 13
- Khanna S, 1988, Convuls Ther, 4, 314
- Klerman GL, 199, Social Morbidity Health Care Utilization J, 265, 742
- Kocabasoglu N, 2004, Eur Neuropsychopharmacol, 14, S304, 10.1016/S0924-977X(04)80382-1 · doi:10.1016/s0924-977x(04)80382-1
- Koran LM, 2007, Am J Psychiatry, 164, 5
- Lee C, 2002, J Clin Psychol Psychother, 58, 1071
- Lenox-Smith AJ, 2003, Br J Gen Pract, 53, 772
- Li D, 2001, J Psychiatry Neurosci, 26, 190
- Lidren DM, 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
- Liebowitz MR, 1988, J Clin Psychiatry, 49, 252
- 10.1002/(SICI)1520-6394(1999)10:3%3C89::AID-DA1%3E3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Livingston MG, 1994, Br J Hosp Med, 51, 281
- Lopes AC, 2008, Biol Psychiaty, 63, 131s, 10.1016/j.biopsych.2007.11.007 · doi:10.1016/j.biopsych.2007.11.007
- López-Ibor JJ, 1975, Neurological treatment in psychiatry, pain and epilepsy, 151
- Lum M, 1990, Biol Psychiatry :A, 27, 164
- Maletzky B, 1994, Convuls Ther, 10, 34
- Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
- Marmar CR, 1996, J Clin Psychiatry, 57, 66
- Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
- Mavissakalian M, 1986, J Clin Psychol, 47, 117
- Meibach RC, 1987, J Clin Psychiatry, 48, 355
- Misri S, 2000, Can Family Phys, 46, 626
- Mohlman J, 2003, Am J Geriatr Psychiatry, 11, 24
- Montoya A, 2002, Neurosurgery, 50, 1043
- Munjack DJ, 1989, J Clin Psychopharmacol, 9, 22
- Munjack DJ, 1990, J Clin Psychiatry, 51, 35
- Nelson J, 1999, Can Soc Clin Pharmacol, 6, 69
- Neylan TC, 2006, Am J Psychiatry, 163, 2186, 10.1176/ajp.2006.163.12.2186 · doi:10.1176/ajp.2006.163.12.2186
- Nicolini H, 2008, Psychol Med, 1
- NIMH 1976. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy E, ECDEU Assessment manual for psychopharmacology. Revised edition. Rockville, MD: NIMH. p 217–222.
- Noyes R, 1996, J Clin Psychiatry, 57, 349
- Nutt DJ, 1998, J Clin Psychiatry, 59, 4
- Ontiveros A, 1992, J Psychiatry Neurosci, 17, 78
- Pastrana Jiménez JI, 2007, Actas Esp Psiquiatr, 35, 351
- Pigott TA, 1992, J Clin Psychopharmacol, 12, 11
- Pollack MH, 2003, Psychopharmacol Bull, 37, 53
- Pollack MH, 1994, J Clin Psychiatry, 55, 200
- Pollack MH, 1996, Psychopharmacol Bull, 32, 667
- Pollack MH, 1997, J Clin Psychiatry, 58, 19
- Pols H, 1993, Acta Psychiatr Belg, 93, 169
- Power KG, 1990, Br J Gen Pract, 40, 289
- Prasko J, 2006, Neuroendocrinol Lett, 27, 473
- Prasko J, 2006, Neuroendocrinol Lett, 27, 327
- 10.1034/j.1600-0447.2001.00263.x · DOI · Paper page
- Ravizza L, 1996, Psychopharmacol Bull, 32, 677
- 10.1037/0022-006X.70.4.86 · doi:10.1037/0022-006x.70.4.86
- Rickels K, 1982, J Clin Psychiatry, 43, 81
- Riddle MA, 1996, Psychopharmacol Bull, 32, 399
- Rizley R, 1986, Psychopharmacol Bull, 22, 167
- Rothbaum B, 1997, Bull Menninger Clinic, 61, 317
- Rothbaum BO, 2008, J Clin Psychiatry, e1
- Rück C, 2006, Capsulotomy in anxiety disorders [thesis]
- 10.1176/appi.ajp.164.2.290 · DOI
- 10.1002/da.20271 · DOI
- Sachdev P, 1995, J Nerv Ment Dis, 183, 408, 10.1097/00005053-199506000-00010 · doi:10.1097/00005053-199506000-00010
- 10.1345/aph.1C040 · doi:10.1345/aph.1c040 · Paper page
- Saxena S, 1996, J Clin Psychiatry, 57, 303
- Seedat S, 2004, J Clin Psychiatry, 65, 244
- Shader RI, 1993, New Engl J Med, 13, 1398
- Sharp DM, 1997, Br J Gen Pract, 47, 150
- Simon NM, 2003, Psychopharmacol Bull, 37, 66
- Simon NM, 2008, J Clin Psychiatry, e1
- Stein DJ, 1999, S Afr Med J, 89, 402
- 10.3109/10401230600948431 · doi:10.3109/10401230600948431
- Stein DJ, 2007, Eur Neuropsychophar17(Suppl, 4, S509, 10.1016/S0924-977X(07)70784-8 · doi:10.1016/s0924-977x(07)70784-8
- Strand M, 1990, J Clin Psychiatry (Suppl), 51, 40
- Telch MJ, 1995, J Consult Clin Psychol, 63, 823, 10.1037/0022-006X.63.5.823 · doi:10.1037/0022-006x.63.5.823
- Tesar GE, 1991, J Clin Psychiatry, 52, 69
- Tiffon L, 1994, J Clin Psychiatry, 55, 66
- Todorov C, 2000, Can J Psychiatry, 45, 257, 10.1177/070674370004500304 · doi:10.1177/070674370004500304
- Turner SM, 1994, J Consult Clin Psychol, 62, 350, 10.1037/0022-006X.62.2.350 · DOI · Paper page
- van Ameringen M, 1993, J Clin Psychiatry, 54, 27
- van der Kolk BA, 1994, J Clin Psychiatry, 55, 517
- Wetherell JL, 2003, J Consult Clin Psychol, 71, 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
- WHO, 1991, Clinical Descriptions and Diagnostic Guidelines
- Woodman CL, 1994, J Clin Psychiatry, 55, 134
- Worthington JJ, 1998, Psychopharmacol Bull, 34, 199
- Zitterl W, 1999, Wien Klin Wochenschr, 111, 439
- Zohar J, 2006, Obsessive-compulsive disorder and comorbidity, 79
Cited by
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Self-citationStein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Self-citationObsessive-compulsive disorder: An integrative genetic and neurobiological perspective
Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3746 · Cited by 793
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citation
Metadata
- Authors
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP TASK FORCE ON TREATMENT GUIDE
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 9
- Issue
- 4
- Pages
- 248-312
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W1966065460
- Cited by
- 854
- References
- 826
- FWCI
- 73.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.